Intestinal Carcinoid Tumor Medication

1. Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer. 2005 Dec 1. 104 (11):2292-309. [QxMD MEDLINE Link].

2. Vinik A, Hughes MS, Feliberti E, et al. Carcinoid Tumors [Updated 2018 Feb 5]. De Groot LJ, Chrousos G, Dungan K, et al, eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000-. [Full Text].

3. Kim JY, Hong SM. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts. Arch Pathol Lab Med. 2016 May. 140 (5):437-48. [QxMD MEDLINE Link].

4. Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA: A Cancer Journal for Clinicians. 2018 Oct 08. 68:471-487.

5. Moris D, Tsilimigras DI, Vagios S, Ntanasis-Stathopoulos I, Karachaliou GS, Papalampros A, et al. Neuroendocrine Neoplasms of the Appendix: A Review of the Literature. Anticancer Res. 2018 Feb. 38 (2):601-611. [QxMD MEDLINE Link].

6. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017 Apr. 18 (4):525-534. [QxMD MEDLINE Link].

7. Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer. 2012. 3:292-302. [QxMD MEDLINE Link].

8. American Cancer Society. Cancer Facts & Figures 2017 (includes the Special Section: Rare Cancers in Adults). 2017. Available at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf.

9. Abou Saleh M, Mansoor E, Anindo M, Isenberg G. Prevalence of Small Intestine Carcinoid Tumors: A US Population-Based Study 2012-2017. Dig Dis Sci. 2018 Dec 5. [QxMD MEDLINE Link].

10. Marshall JB, Bodnarchuk G. Carcinoid tumors of the gut. Our experience over three decades and review of the literature. J Clin Gastroenterol. 1993 Mar. 16(2):123-9. [QxMD MEDLINE Link].

11. Loughrey PB, Zhang D, Heaney AP. New Treatments for the Carcinoid Syndrome. Endocrinol Metab Clin North Am. 2018 Sep. 47 (3):557-576. [QxMD MEDLINE Link].

12. Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Biomed Res Int. 2017. 2017:9856140. [QxMD MEDLINE Link].

13. Raut CP, Kulke MH, Glickman JN, Swanson RS, Ashley SW. Carcinoid Tumors. Current Problems in Surgery. 2006. 43:391-450. [Full Text].

14. Oberndorfer S. Karzinoide tumoren des du¨nndarms. Frankfurt Zietschrift fur Pathologie. 1907. 1:426-429.

15. Thorson A, Biorck G, Bjorkman G, Waldenstrom J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J. 1954 Jun. 47(5):795-817. [QxMD MEDLINE Link].

16. Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist. 2008 Dec. 13 (12):1255-69. [QxMD MEDLINE Link].

17. Pearse AG. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem. 1969 May. 17(5):303-13. [QxMD MEDLINE Link].

18. Öberg, K. Chapter 43 - Neuroendocrine Gastrointestinal and Lung Tumors (Carcinoid Tumors), the Carcinoid Syndrome, and Related Disorders. Melmed S, Polonsky KS, Larsen RP, Kronenberg HM, eds. Williams Textbook of Endocrinology. 13th ed. Philadelphia, PA: Elsevier, Inc.; 2016. 1833-1853.

19. Klöppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2011 Oct. 18 Suppl 1:S1-16. [QxMD MEDLINE Link].

20. Xavier S, Rosa B, Cotter J. Small bowel neuroendocrine tumors: From pathophysiology to clinical approach. World J Gastrointest Pathophysiol. 2016 Feb 15. 7 (1):117-24. [QxMD MEDLINE Link].

21. Hande, KR. Chapter 232 - Neuroendocrine Tumors and the Carcinoid Syndrome. Goldman Lee, Schafer AI, eds. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier; 2016. 1557-1560.

22. Hirabayashi K, Zamboni G, Nishi T, Tanaka A, Kajiwara H, Nakamura N. Histopathology of gastrointestinal neuroendocrine neoplasms. Front Oncol. 2013. 3:2. [QxMD MEDLINE Link].

23. Cingam SR, Karanchi H. Cancer, Carcinoid. 2018 Jan. [QxMD MEDLINE Link]. [Full Text].

24. Stålberg P, Westin G, Thirlwell C. Genetics and epigenetics in small intestinal neuroendocrine tumours. J Intern Med. 2016 Dec. 280 (6):584-594. [QxMD MEDLINE Link].

25. Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes. 2018 Feb. 25 (1):22-35. [QxMD MEDLINE Link].

26. Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg. 1999 Jun. 229 (6):815-21; discussion 822-3. [QxMD MEDLINE Link].

27. Szilvas A, Szekely G, Szilvasi I, Sagi S, Jakab F. The importance of follow-up examinations in patients with carcinoid tumor. Hepatogastroenterology. 2003 Sep-Oct. 50(53):1452-3. [QxMD MEDLINE Link].

28. Leoncini E, Carioli G, La Vecchia C, Boccia S, Rindi G. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2016 Jan. 27 (1):68-81. [QxMD MEDLINE Link].

29. American Cancer Society. What are the key statistics about gastrointestinal carcinoid tumors?. American Cancer Society. Available at http://www.cancer.org/cancer/gastrointestinalcarcinoidtumor/detailedguide/gastrointestinal-carcinoid-tumors-key-statistics. September 24, 2018; Accessed: December 15, 2021.

30. Kharazmi E, Pukkala E, Sundquist K, Hemminki K. Familial risk of small intestinal carcinoid and adenocarcinoma. Clin Gastroenterol Hepatol. 2013 Aug. 11(8):944-9. [QxMD MEDLINE Link].

31. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20. 26 (18):3063-72. [QxMD MEDLINE Link].

32. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1. 3 (10):1335-1342. [QxMD MEDLINE Link].

33. Noone AM, Howlader N, Krapcho M, et al (eds). Annual SEER Delay-adjusted Incidence, SEER Incidence and US Death Rates. SEER Cancer Statistics Review, 1975-2015. 2018 Apr. Available at https://seer.cancer.gov/csr/1975_2015/results_merged/topic_annualrates.pdf.

34. Sackstein PE, O'Neil DS, Neugut AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018 Aug. 45 (4):249-258. [QxMD MEDLINE Link].

35. Lee MR, Harris C, Baeg KJ, Aronson A, Wisnivesky JP, Kim MK. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States. Clin Gastroenterol Hepatol. 2018 Dec 20. [QxMD MEDLINE Link].

36. Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013 Dec. 24 (12):3040-4. [QxMD MEDLINE Link].

37. Deans GT, Spence RA. Neoplastic lesions of the appendix. Br J Surg. 1995 Mar. 82(3):299-306. [QxMD MEDLINE Link].

38. Goodman MT, Matsuno RK, Shvetsov YB. Racial and ethnic variation in the incidence of small-bowel cancer subtypes in the United States, 1995-2008. Dis Colon Rectum. 2013 Apr. 56(4):441-8. [QxMD MEDLINE Link].

39. Taghavi S, Jayarajan SN, Powers BD, Davey A, Willis AI. Examining rectal carcinoids in the era of screening colonoscopy: a surveillance, epidemiology, and end results analysis. Dis Colon Rectum. 2013 Aug. 56(8):952-9. [QxMD MEDLINE Link].

40. Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers (Basel). 2021 Feb 2. 13 (3):[QxMD MEDLINE Link]. [Full Text].

41. Saxena A, Chua TC, Sarkar A, et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery. 2011 Feb. 149(2):209-20. [QxMD MEDLINE Link].

42. Jacobs RE, Bai S, Hindman N, Shah PC. Carcinoid abdominal crisis: a case report. J Surg Oncol. 2014 Sep. 110 (3):348-51. [QxMD MEDLINE Link].

43. Kim JY, Hong SM. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts. Arch Pathol Lab Med. 2016 May. 140 (5):437-48. [QxMD MEDLINE Link].

44. Massironi S, Rossi RE, Casazza G, Conte D, Ciafardini C, Galeazzi M, et al. Chromogranin A in Diagnosing and Monitoring Patients with Gastro-Entero-Pancreatic Neuroendocrine Neoplasms. A Large Series from a Single Institution. Neuroendocrinology. 2014 Nov 18. [QxMD MEDLINE Link].

45. Modlin IM, Aslanian H, Bodei L, Drozdov I, Kidd M. A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors. Endocr Connect. 2014 Dec. 3(4):215-23. [QxMD MEDLINE Link].

46. Ruszniewski P, Amouyal P, Amouyal G, Grange JD, Mignon M, Bouche O, et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery. 1995 Jun. 117(6):629-35. [QxMD MEDLINE Link].

47. Sugimoto E, Lorelius LE, Eriksson B, Oberg K. Midgut carcinoid tumours. CT appearance. Acta Radiol. 1995 Jul. 36(4):367-71. [QxMD MEDLINE Link].

48. Turner JR. The Gastrointestinal Tract. Kumar V, Abbas AK, Aster JC, eds. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA: Elsevier Inc; 2015. 749-819.

49. Diaco DS, Hajarizadeh H, Mueller CR, Fletcher WS, Pommier RF, Woltering EA. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg. 1995 May. 169(5):523-8. [QxMD MEDLINE Link].

50. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10. 378(9808):2005-12. [QxMD MEDLINE Link].

51. FDA approves new treatment for certain digestive tract cancers. U.S. Food & Drug Administration. Available at https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm594043.htm?elqtrackid=3866a921a66f4a658a229f679f663d96. January 26, 2018; Accessed: December 15, 2021.

52. [Guideline] Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE. J Nucl Med. 2019 Jul. 60 (7):937-943. [QxMD MEDLINE Link]. [Full Text].

53. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, et al. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017 Jan. 35 (1):14-23. [QxMD MEDLINE Link].

54. Cashin P, Nygren P, Hellman P, et al. Appendiceal adenocarcinoids with peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy: a retrospective study of in vitro drug sensitivity and survival. Clin Colorectal Cancer. 2011 Jun. 10(2):108-12. [QxMD MEDLINE Link].

55. McDermott FD, Heeney A, Courtney D, Mohan H, Winter D. Rectal carcinoids: a systematic review. Surg Endosc. 2014 Jul. 28(7):2020-6. [QxMD MEDLINE Link].

56. Mani S, Modlin IM, Ballantyne G, Ahlman H, West B. Carcinoids of the rectum. J Am Coll Surg. 1994 Aug. 179(2):231-48. [QxMD MEDLINE Link].

57. Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg. 2005 Jun. 241(6):839-45; discussion 845-6. [QxMD MEDLINE Link].

58. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. 1986 Jul. 147(1):149-54. [QxMD MEDLINE Link].

59. Altieri B, Barrea L, Modica R, Muscogiuri G, Savastano S, Colao A, et al. Nutrition and neuroendocrine tumors: An update of the literature. Rev Endocr Metab Disord. 2018 Jun. 19 (2):159-167. [QxMD MEDLINE Link].

60. [Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors, Version 4.2021. NCCN. Available at http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. December 14, 2021; Accessed: December 15, 2021.

61. Bosman FT, Carneiro F, Hruban RH, Theise ND. World Health Organization Classification of Tumours of the Digestive System. Lyons, France: IARC; 2010.

62. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006 Oct. 449 (4):395-401. [QxMD MEDLINE Link]. [Full Text].

63. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007 Oct. 451 (4):757-62. [QxMD MEDLINE Link]. [Full Text].

64. Amin, MB. AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017.

65. [Guideline] Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jul. 31 (7):844-860. [QxMD MEDLINE Link]. [Full Text].

66. [Guideline] Ramage JK, Ahmed A, Ardill J, et al., UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012 Jan. 61 (1):6-32. [QxMD MEDLINE Link]. [Full Text].

67. [Guideline] Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May. 42 (4):557-77. [QxMD MEDLINE Link]. [Full Text].

68. [Guideline] Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010 Aug. 39 (6):735-52. [QxMD MEDLINE Link]. [Full Text].

69. [Guideline] Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology. 2016. 103 (2):119-24. [QxMD MEDLINE Link].

70. [Guideline] Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, et al. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology. 2016. 103 (2):139-43. [QxMD MEDLINE Link].

71. [Guideline] Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology. 2016. 103 (2):125-38. [QxMD MEDLINE Link].

72. Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, et al. ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology. 2016. 103 (2):144-52. [QxMD MEDLINE Link].

73. Chapman WC, Debelak JP, Wright Pinson C, Washington MK, Atkinson JB, Venkatakrishnan A, et al. Hepatic cryoablation, but not radiofrequency ablation, results in lung inflammation. Ann Surg. 2000 May. 231 (5):752-61. [QxMD MEDLINE Link].

74. Öberg K. Carcinoid Tumors: Current Concepts in Diagnosis and Treatment. Oncologist. 1998. 3(5):339-345. [QxMD MEDLINE Link].

75. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003 Feb 15. 97(4):934-59. [QxMD MEDLINE Link].

76. Tsoli M, Kaltsas G. Carcinoid Syndrome. Huhtaniemi I, Martini L. Encyclopedia of Endocrine Diseases. Second Edition. Academic Press; 2019. 2: [Full Text].

77. Eggenberger JC. Carcinoid and other neuroendocrine tumors of the colon and rectum. Clin Colon Rectal Surg. 2011 Sep. 24 (3):129-34. [QxMD MEDLINE Link]. [Full Text].

78. Moris D, Ntanasis-Stathopoulos I, Tsilimigras DI, Vagios S, Karamitros A, Karaolanis G, et al. Update on Surgical Management of Small Bowel Neuroendocrine Tumors. Anticancer Res. 2018 Mar. 38 (3):1267-1278. [QxMD MEDLINE Link].

79. Pasricha G, Padhi P, Daboul N, Monga DK. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review. Clin Ther. 2017 Nov. 39 (11):2146-2157. [QxMD MEDLINE Link]. [Full Text].

80. Bergsland EK. The evolving landscape of neuroendocrine tumors. Semin Oncol. 2013 Feb. 40 (1):4-22. [QxMD MEDLINE Link].

81. Byrne RM, Pommier RF. Small Bowel and Colorectal Carcinoids. Clin Colon Rectal Surg. 2018 Sep. 31 (5):301-308. [QxMD MEDLINE Link].

82. Moris D, Tsilimigras DI, Vagios S, Ntanasis-Stathopoulos I, Karachaliou GS, Papalampros A, et al. Neuroendocrine Neoplasms of the Appendix: A Review of the Literature. Anticancer Res. 2018 Feb. 38 (2):601-611. [QxMD MEDLINE Link].

Rachel E Lewis, MD Resident Physician, Resident Research Fellowship in General Surgery, Department of Surgery, Division of Trauma, Critical Care, GI, and Nutrition, University of Tennessee Health Science Center College of Graduate Health Sciences

Rachel E Lewis, MD is a member of the following medical societies: American Medical Association, Knoxville Academy of Medicine

Disclosure: Nothing to disclose.

Keith D Gray, MD, FACS Chief, Division of Surgical Oncology, Assistant Professor, Department of Surgery, University of Tennessee Graduate School of Medicine; Medical Director, Gastrointestinal Tumor Service (GITS), The University of Tennessee Medical Center Cancer Institute; Clinical Specialist, Department of Surgery, The University of Tennessee Medical Center

Keith D Gray, MD, FACS is a member of the following medical societies: American Association for Cancer Research, American College of Surgeons, National Medical Association, Society of Surgical Oncology, Southeastern Surgical Congress

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Benjamin Movsas, MD

Benjamin Movsas, MD is a member of the following medical societies: American College of Radiology, American Radium Society, American Society for Radiation Oncology

Disclosure: Nothing to disclose.

N Joseph Espat, MD, MS, FACS Harold J Wanebo Professor of Surgery, Assistant Dean of Clinical Affairs, Boston University School of Medicine; Chairman, Department of Surgery, Director, Adele R Decof Cancer Center, Roger Williams Medical Center

N Joseph Espat, MD, MS, FACS is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Parenteral and Enteral Nutrition, American Society of Clinical Oncology, Americas Hepato-Pancreato-Biliary Association, Association for Academic Surgery, Central Surgical Association, Chicago Medical Society, International Hepato-Pancreato-Biliary Association, Pancreas Club, Sigma Xi, The Scientific Research Honor Society, Society for Leukocyte Biology, Society for Surgery of the Alimentary Tract, Society of American Gastrointestinal and Endoscopic Surgeons, Society of Surgical Oncology, Society of University Surgeons, Southeastern Surgical Congress, Southern Medical Association, Surgical Infection Society

Disclosure: Nothing to disclose.

Alan A Saber, MD, MS, FACS, FASMBS Director of Bariatric and Metabolic Surgery, University Hospitals Case Medical Center; Surgical Director, Bariatric Surgery, Metabolic and Nutrition Center, University Hospitals Digestive Health Institute; Associate Professor of Surgery, Case Western Reserve University School of Medicine

Alan A Saber, MD, MS, FACS, FASMBS is a member of the following medical societies: American College of Surgeons, American Society for Gastrointestinal Endoscopy, American Society for Metabolic and Bariatric Surgery

Disclosure: Nothing to disclose.

Lodovico Balducci, MD Professor, Oncology Fellowship Director, Department of Internal Medicine, Division of Adult Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine

Lodovico Balducci, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association for Cancer Research, American College of Physicians, American Geriatrics Society, American Society of Hematology, New York Academy of Sciences, American Society of Clinical Oncology, Southern Society for Clinical Investigation, International Society for Experimental Hematology, American Federation for Clinical Research, American Society of Breast Disease

Disclosure: Nothing to disclose.

Hemant Singhal, MD, MBBS, MBA, FRCS, FRCS(Edin), FRCSC Consultant Breast Surgeon, Clementine Churchill Hospital; Consultant Breast Surgeon, Harley Street Breast Clinic, UK

Hemant Singhal, MD, MBBS, MBA, FRCS, FRCS(Edin), FRCSC is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of Edinburgh

Disclosure: Nothing to disclose.

Michael Kent McLeod, MD, MBA, FACE, FACS Associate Chair, Professor of Surgery and Program Director, Integrated General Surgery Program, Department of Surgery, Michigan State University College of Human Medicine

Michael Kent McLeod, MD, MBA, FACE, FACS is a member of the following medical societies: American Association of Clinical Endocrinologists, American Association of Endocrine Surgeons, American College of Surgeons, American Medical Association, Association for Academic Surgery, Central Surgical Association, International Association of Endocrine Surgeons, Michigan State Medical Society, Midwest Surgical Association, National Medical Association, Society of American Gastrointestinal and Endoscopic Surgeons, Western Surgical Association

Disclosure: Nothing to disclose.

Kanchan Kaur, MBBS, MS (GenSurg), MRCSEd Consulting Breast and Oncoplastic Surgeon, Medanta, The Medicity, India

Disclosure: Nothing to disclose.

Charles Zammit, MD Senior Specialist Registrar, Department of Surgery, Breast Unit Charing Cross Hospital of London, UK

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article